DescriptionCannabidiol, sometimes also referred to as cannabidiol, is an important phytochemical found in many species of the cannabis plant. It is among the seven known naturally occurring non-carcinogens. Cannabidiol or CBD is the only chemical in nature that has been proven to have significant therapeutic value in human beings. Cannabidiol, or CBD, is produced by the hemp plant, cannabis, in its most essential form, although other forms of CBD are created synthetically. The name CBD comes from the Sanskrit word ‘kunda,’ which means pure or simple. It is one of the Chandan-Bala-Laxadi-Qadha (medicine) of India, considered to be very important in the management of many diseases including Parkinson’s disease, epilepsy, chronic pain and spasticity.
Biochemists believe that CBD may help prevent the degeneration of brain cells that cause Alzheimer’s disease and also reduce the inflammation of the hippocampus, one of two parts of the brain that becomes overactive in patients with Alzheimer’s. In June 2021, the United States government filed a lawsuit against three manufacturers of medical marijuana claiming that the ingredients in these products caused changes to test subjects that later led to memory loss, drowsiness and inability to remember things. According to the United States House of Representatives, the plaintiffs “plaintiffs maintain that the ingredients in defendant’s product (including the CBD) have both immediate and long term adverse physical health effects on their users’ such as coughing, nausea, lethargy, short term memory loss, anxiety, coughing, seizures, driving under the influence, and unstable moods and sleep disorders.” The suit further claims that because the ingredients CBD and THC have not been approved by the FDA as medicines, they cannot be controlled by the federal government. Consequently, the three companies are being charged with criminal conspiracy to manufacture drugs with controlled substances and violations of the Controlled Substances Act. Visit here for more information about bluebonnetvapor.com.
While there is no concrete evidence that CBD can help treat or prevent the symptoms of various diseases, some health experts believe it may be able to relieve anxiety, nausea, and chronic pain, which are often present symptoms of ailments like arthritis and cancer. In fact, CBD has been a subject of much research by scientists who are examining the effect of this plant on neurological functions and the neuroendocrinological processes that occur in the body. Most of these studies have concluded that CBD may be effective in reducing the symptoms of some forms of anxiety, depression, epilepsy, Crohn’s disease, glaucoma, and cancer. In certain cases, CBD has been found to relieve the symptoms of Parkinson’s disease and treat sleep problems associated with bipolar disorder and psychosis.
A number of interesting studies have been conducted on the impact of CBD on cholesterol and blood pressure levels. These investigations seem to indicate that CBD may lower total cholesterol levels, but the results of these studies were inconclusive due to the small number of subjects included in the studies. No studies have directly examined the effect of CBD on heart disease, despite the fact that CBD is believed to improve the function of the cardiovascular systems. One study found that CBD decreased the risk of sudden death in people with previous cardiac conditions, while another found that CBD may prevent the progression of congestive heart failure in people with established cardiac disease.
The most recent of the medical research involving CBD is the study conducted by the University of Kentucky. According to the researchers, CBD is believed to be effective in treating pain and depression associated with multiple sclerosis. They suggest that CBD might have the potential to reduce the occurrence and severity of dyskinesia–a decrease in muscle coordination and movement–in people with multiple sclerosis. The researchers caution, however, that there is still insufficient evidence to suggest that CBD is effective in treating pain or depression associated with MS.
One pharmaceutical company has conducted clinical trials using CBD sativex for patients with multiple sclerosis. At least one company involved in the development of CBD has filed a patent on CBD sativex. In November of 2021, the US Patent and Trademark Office approved the patent. The USPTO granted final approval to an affiliated firm, Celogen, for a six-month trial of CBD sativex in pediatric patients with dystonia. According to the USPTO, the trial showed that sativex may be useful in treating various dyskinesias, including brachycephaly, andaxgeic dystrophy, scapho-axillary transition phase, progressive carotid artery disease, dysplasia, spasticity, limb-girdle muscular dysplasia and restless leg syndrome. Based on this information, a potential market for CBD is beginning to emerge.